CD68 and hepatocellular carcinoma: A combination of doxorubicin-loaded liposomes and clodronate-loaded liposomes has been utilized in HCC therapy and after intra-spleen injection, it was found that they are able to deplete macrophages and reduce number of hepatic CD68 + macrophages that these changes in TME can result in significant reduction in HCC progression [215].